Hospitales Universitarios Virgen Macarena y Virgen del Rocío

Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus (2025) Brancaccio G, Briatico G, Apalla Z, Dummer R, Eklind J, Seguin NB, Dreno B, et al. Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications (2025) León-Jiménez D, Sridhar VS, López-Mendoza M, Scholtes RA, Schmieder R, Cherney DZ, van Raalte DH, et al. Journal article, Review article Hodgkin lymphoma: hypodense lesions in mediastinal masses (2024) Damek A, Kurch L, Franke FC, Attarbaschi A, Beishuizen A, Cepelova M, Ceppi F, et al. Journal article Technical considerations for isolated limb perfusion: A consensus paper (2024) Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, et al. Journal article, Review article Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024) Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey (2023) Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching P, et al. Journal article Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study (2023) Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, et al. Journal article Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution